drugset / Trial / NCT00593008
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
Phase 1
Terminated
5 enrolled
Massachusetts General Hospital
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Temsirolimus | Small molecule | — | Intravenous |